Patents by Inventor David Busha

David Busha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240041979
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
    Type: Application
    Filed: May 11, 2022
    Publication date: February 8, 2024
    Inventors: Thomas BRENNAN, David BELLOVIN, Barbara SENNINO, David BUSHA
  • Publication number: 20220142919
    Abstract: The present invention provides dynamically covalent polymeric hydrogel systems for encapsulating and stabilizing bioactive therapeutic agents (e.g., proteins, cells, viruses, and vaccines) from environmental stressors, obviating standard refrigeration requirements, and decreasing transportation and storage costs of temperature-sensitive biomolecules. Described herein are dynamic polymeric hydrogel compositions comprising a therapeutic agent and a combination of phenylboronic acid- and 1,2-diol-modified multi-arm polyethylene glycol (PEG) polymer backbones. Methods of encapsulating and stabilizing bioactive therapeutic agents within the dynamic polymeric hydrogel compositions are also provided. Also described are methods for releasing stabilized therapeutic agents from hydrogel encapsulation.
    Type: Application
    Filed: March 5, 2020
    Publication date: May 12, 2022
    Applicant: Nanoly Bioscience, Inc.
    Inventors: Bruno Marco-Dufort, Mark W. Tibbitt, Balaji V. Sridhar, John R. Janczy, David Busha, Margaret Best
  • Patent number: 11098103
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: August 24, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
  • Publication number: 20190202889
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 4, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas BRENNAN, David BELLOVIN, David BUSHA, Barbara SENNINO
  • Publication number: 20190194288
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Application
    Filed: March 7, 2019
    Publication date: June 27, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas BRENNAN, David BELLOVIN, David BUSHA, Barbara SENNINO
  • Patent number: 10273281
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: April 30, 2019
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
  • Publication number: 20170145071
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Application
    Filed: November 1, 2016
    Publication date: May 25, 2017
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
  • Patent number: 7290788
    Abstract: A bracket is provided for connecting an airbag module to a structural member in an automotive vehicle. The bracket provides three degrees to freedom to allow the fit and finish of the interior panels to be determined without being affected by the rigid connection between the airbag module and the structural member. Holes are also provided in the bracket for tuning energy management.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: November 6, 2007
    Assignee: Visteon Global Technologies, Inc.
    Inventors: Glenn E. Tomford, David Busha, Donald Cvengros, D'Andre Sakhone
  • Publication number: 20050046155
    Abstract: A bracket is provided for connecting an airbag module to a structural member in an automotive vehicle. The bracket provides three degrees to freedom to allow the fit and finish of the interior panels to be determined without being affected by the rigid connection between the airbag module and the structural member. Holes are also provided in the bracket for tuning energy management.
    Type: Application
    Filed: September 3, 2003
    Publication date: March 3, 2005
    Inventors: Glenn Tomford, David Busha, Donald Cvengros, Sakhone D'Andre